0001144204-14-063826.txt : 20141030 0001144204-14-063826.hdr.sgml : 20141030 20141030095532 ACCESSION NUMBER: 0001144204-14-063826 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20141030 FILED AS OF DATE: 20141030 DATE AS OF CHANGE: 20141030 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BIO BLAST PHARMA LTD. CENTRAL INDEX KEY: 0001596812 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: L3 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36578 FILM NUMBER: 141181906 BUSINESS ADDRESS: STREET 1: 35 AHAD HA'AM ST CITY: TEL AVIV STATE: L3 ZIP: 65202 BUSINESS PHONE: 972 (0) 3 7326616 MAIL ADDRESS: STREET 1: 35 AHAD HA'AM ST CITY: TEL AVIV STATE: L3 ZIP: 65202 6-K 1 v392648_6k.htm FORM 6-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

For the month of: October 2014

BIO BLAST PHARMA LTD.

(Translation of registrant's name into English)

37 Dereh Menechem Begin St., 15^th Floor

Tel Aviv 6522042 Israel

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F x Form 40-F ¨

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(1):_____

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(7):_____

Indicate by check mark, whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes ¨ No x

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b):_____

Results of the Extraordinary General Meeting of Shareholders

At the extraordinary general meeting of shareholders held on October 30, 2014, the shareholders of Bio Blast Pharma Ltd. approved all agenda items as originally proposed.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

		Bio Blast Pharma Ltd. (Registrant)



		By	/s/ Dalia Megiddo
		Name: Dalia Megiddo
		Chief Executive Officer and President

Date: October 30, 2014